All antibodies are NOT created equal: Comprehensive profiling of SARS-CoV-2 antibodies
25 Sep 2020

Detecting antibodies that confer effective immunity is crucially important to understand a patient’s immune response to SARS-CoV-2. In particular, the ability to quantify the virus-neutralizing capacity of the immune system is key to support the development of suitable vaccines and antibody-based treatments such as convalescent plasma therapies.

This talk outlines our efforts in assessing the immune response in COVID-19 patients by use of a novel microfluidic in-solution immunoassay platform. With this new approach we were able to comprehensivley profile SARS-CoV-2 antibodies directly in minimally diluted serum of these patients.

During the event, we will be looking into:

  • Understand drawbacks of standard immunoassays such as ELISA tests
  • Understand that affinity-based antibody profiling is key for a comprehensive understanding of the immune response against SARS-CoV-2
  • Learn about ability to assess the immune response of COVID-19 patients directly in minimally diluted serum by use of our novel in-solution immunoassay platform
  • Understand how our technology can be leveraged by scientists in the fight against COVID-19

Fluidic Analytics